Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Loading...
Embargo End Date
ICR Authors
Authors
Drew, Y
Kim, J-W
Penson, RT
O'Malley, DM
Parkinson, C
Roxburgh, P
Plummer, R
Im, S-A
Imbimbo, M
Ferguson, M
Rosengarten, O
Steeghs, N
Kim, MH
Gal-Yam, E
Tsoref, D
Kim, J-H
You, B
De Jonge, M
Lalisang, R
Gort, E
Bastian, S
Meyer, K
Feeney, L
Baker, N
Ah-See, M-L
Domchek, SM
Banerjee, S
MEDIOLA Investigators,
Kim, J-W
Penson, RT
O'Malley, DM
Parkinson, C
Roxburgh, P
Plummer, R
Im, S-A
Imbimbo, M
Ferguson, M
Rosengarten, O
Steeghs, N
Kim, MH
Gal-Yam, E
Tsoref, D
Kim, J-H
You, B
De Jonge, M
Lalisang, R
Gort, E
Bastian, S
Meyer, K
Feeney, L
Baker, N
Ah-See, M-L
Domchek, SM
Banerjee, S
MEDIOLA Investigators,
Document Type
Journal Article
Date
2024-01-05
Date Accepted
2023-11-06
Abstract
PURPOSE: Early results from the phase II MEDIOLA study (NCT02734004) in germline BRCA1- and/or BRCA2-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) showed promising efficacy and safety with olaparib plus durvalumab. We report efficacy and safety of olaparib plus durvalumab in an expansion cohort of women with gBRCAm PSROC (gBRCAm expansion doublet cohort) and two cohorts with non-gBRCAm PSROC, one of which also received bevacizumab (non-gBRCAm doublet and triplet cohorts). PATIENTS AND METHODS: In this open-label, multicenter study, PARP inhibitor-naïve patients received olaparib plus durvalumab treatment until disease progression; the non-gBRCAm triplet cohort also received bevacizumab. Primary endpoints were objective response rate (ORR; gBRCAm expansion doublet cohort), disease control rate (DCR) at 24 weeks (non-gBRCAm cohorts), and safety (all cohorts). RESULTS: The full analysis and safety analysis sets comprised 51, 32, and 31 patients in the gBRCAm expansion doublet, non-gBRCAm doublet, and non-gBRCAm triplet cohorts, respectively. ORR was 92.2% [95% confidence interval (CI), 81.1-97.8] in the gBRCAm expansion doublet cohort (primary endpoint); DCR at 24 weeks was 28.1% (90% CI, 15.5-43.9) in the non-gBRCAm doublet cohort (primary endpoint) and 74.2% (90% CI, 58.2-86.5) in the non-gBRCAm triplet cohort (primary endpoint). Grade ≥ 3 adverse events were reported in 47.1%, 65.6%, and 61.3% of patients in the gBRCAm expansion doublet, non-gBRCAm doublet, and non-gBRCAm triplet cohorts, respectively, most commonly anemia. CONCLUSIONS: Olaparib plus durvalumab continued to show notable clinical activity in women with gBRCAm PSROC. Olaparib plus durvalumab with bevacizumab demonstrated encouraging clinical activity in women with non-gBRCAm PSROC. No new safety signals were identified.
Citation
Clinical Cancer Research, 2024, 30 (1), pp. 50 - 62
Source Title
Clinical Cancer Research
Publisher
AMER ASSOC CANCER RESEARCH
ISSN
1078-0432
eISSN
1557-3265
1557-3265
1557-3265